Cases & Deals

  • Home
  • Practices
  • Medicxi Ventures participates in €3.3 million investment in Yukin Therapeutics

Share

Medicxi Ventures participates in €3.3 million investment in Yukin Therapeutics

April 2019

Client(s) Medicxi Ventures (UK) LLP

Jones Day represented Medicxi Ventures (UK) LLP in connection with its €3.3 million (US$3.7 million) investment in Yukin Therapeutics, a French-based company engaged in the research and development of small molecules targeting the kinase NIK for the treatment of cancer and inflammatory diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.